Frost & Sullivan Analyst Briefing Presentation on 'Cardiovascular Drugs Market in KSA & UAE

1. Cardiovascular Drugs Market in KSA & UAE
- What’s in store for Pharmacos?
Supratim Majumdar, Industry Manager
Healthcare
20th April, 2011

2. Today’s Presenters
Supratim Majumdar, Industry Analyst
Frost & Sullivan
Tanu Chopra, Assistant Manager, Corporate Communications,
Frost & Sullivan
2

3. Research Aim and Key Deliverables
Research Aim
• The aim of this research service is to present an analysis of the Cardiovascular Drugs Market
in KSA and UAE.
Key Deliverables
• Quantifying the size and growth forecasts of the cardiovascular drugs market in KSA and
UAE from 2010 to 2017 by product segments
• Providing insight into the industry challenges, market drivers, and market restraints during the
forecast period
• Identifying key participants of the market and quantifying company market shares by product
segments
• Providing further insight into the competitive environment
• Identifying opportunities for current and new market participants based on a strength,
weakness, opportunities, and threats (SWOT) analysis
3

4. Market Scope and Segmentation
Market Scope:
Countries covered for the study are:
Kingdom of Saudi Arabia (KSA)
United Arab Emirates (UAE)
Market Segmentation:
Antihypertensive
Market Segments
Antidyslipidemic
Others
4

5. Market Overview
Cardiovascular disease (CVD) is the main cause of disability and premature death
through the world in general and in KSA and UAE in particular.
KSA and UAE population is achieving high percentages of cardiovascular diseases
prevalence, due to sedentary lifestyle, mimicking western food habits, smoking, etc.
The total KSA cardiovascular drugs market generated revenue of $172.8 million in
2010.Revenues are expected to increase to $537.1 with a CAGR of 17.6 percent.
The total UAE cardiovascular drugs market generated revenue of $100.2 million in
2010.Revenues are expected to increase to $292.4 million with a CAGR of 16.5 percent.
Within the market, antihypertensives held the largest share of almost 60.0 percent of the
revenues in 2010, followed by antidyslipidemics, which help a 37.0 percent share and the
others segment with around a share of 3.0 percent.
5

6. Market Overview Contd.
At present, there are around 16 players competing in the KSA market. Around 80.0 of the
total market is controlled by top 4 players.
In UAE, around 11 participants are competing in the cardiovascular drugs market. Top 4
players command around 60.0 percent of the market.
Within antihypertensives, ACE Inhibitors and ARBs are most preferred and used drug
classes in both of the markets.
Statins is the undisputed most used drug class among antidyslipidemics in both the
markets.
Foreign pharmaceutical companies command the majority market share due to innovative
products, generic coverage by local companies, fewer number of local companies with
limited manufacturing capacity.
6

7. Market Drivers and Restraints
Short Term Mid Term Long Term
Rising incidence of life style diseases
Mandatory health insurance
Drivers
Rising ageing population
Rising health awareness
Newer & easier launches of combination drugs
Patent incidence launches of lesser value generics
Rising expiry andof life style diseases
Restraints
Mandatory health insurance of generics
Government promoting usage
Stringent regulatory system
Low patient compliance
7

8. Current Market Size and Growth Trends: KSA
Cardiovascular Drugs Market: Revenue Forecast (KSA), 2010 - 2017
600
500
Market Revenue (Million USD)
400
300
200
100
0
2010 2017
Market Revenue(Million USD) 173 537
Years
8

9. Cardiovascular Drugs Market – Segment Analysis: KSA
Cardiovascular Drugs Market: Market Segments (KSA), 2010
Lipid Lowering
37%
Antihypertensive
60%
Others
3%
9

10. Market Share Analysis: KSA
Total Cardiovascular Drugs Market: Market Share Analysis (KSA), 2010
Others
20%
Top 4 Players
80%
10

11. Current Market Size and Growth Trends: UAE
Cardiovascular Drugs Market: Revenue Forecast (UAE), 2010 - 2017
300
Market Revenue (Million USD)
200
100
0
2010 2017
Market Revenue(Million USD) 100 292
Years
11

12. Cardiovascular Drugs Market – Segment Analysis: UAE
Cardiovascular Drugs Market Segment (UAE), 2010
Anti
Others, Hypertensive
2.41% 61.2 %
Lipid
Lowering,
36.54%
12

13. Market Share Analysis: UAE
Total Cardiovascular Drugs Market: Market Share of Key Players (UAE), 2010
Others
20% Top 4 Players
80%
13

14. Next Steps
Request a proposal for or Growth Partnership Services or Growth
Consulting Services to support you and your team to accelerate the growth of
your company. (myfrost@frost.com) 1-877-GoFrost (1-877-463-7678)
Join us at our annual Growth, Innovation, and Leadership 2011: A Frost &
Sullivan Global Congress on Corporate Growth (www.gil-global.com)
Register for the next Chairman’s Series on Growth: Driving Innovation – The
What, Why, and How. Visions and Benchmarks as the Innovation Key
(October 5th) (http://www.frost.com/growth)
Register for Frost & Sullivan’s Growth Opportunity Newsletter and keep
abreast of innovative growth opportunities
(www.frost.com/news)
14

15. Your Feedback is Important to Us
What would you like to see from Frost & Sullivan?
Growth Forecasts?
Competitive Structure?
Emerging Trends?
Strategic Recommendations?
Other?
Please inform us by rating this presentation.
Frost & Sullivan’s Growth Consulting can assist with your growth strategies
15

16. Follow Frost & Sullivan on Facebook, LinkedIn,
SlideShare, and Twitter
http://www.facebook.com/FrostandSullivan
http://www.linkedin.com/companies/4506
http://www.slideshare.net/FrostandSullivan
http://twitter.com/frost_sullivan
16

17. For Additional Information
Tanu Chopra Supratim Majumdar
Asst. Manager - Corporate Industry Analyst
Communications - MENA Healthcare
(91) 22 66072037 (033) 6160-6666
tanu.chopra@frost.com supratim.majumdar@frost.com
Anish Charles
Dr. Ajay Prasad Sharma
Asst Manger Corporate
Communications – South Asia Industry Manager
(91) 22 66072019 Healthcare
anishc@frost.com (022) 6160-6666
AjaykumarS@frost.com
17